Beneficios del cannabidiol proveniente de Cannabis sativa sobre enfermedades neurodegenerativas: una revisión sobre su implementación en la medicina moderna
Barra lateral del artículo
Contenido principal del artículo
Resumen
El cannabidiol es uno de los compuestos más abundantes de la Cannabis sativa, y es sumamente importante debido a su alto potencial medicinal, especialmente en referencia a las enfermedades neurodegenerativas. A través de su intervención fisiológica realizada por medio del sistema endocannabinoide y sus propiedades antioxidantes, es capaz de prevenir fenómenos como la apoptosis neuronal, y asistir con el manejo de los síntomas más prevalentes, como la inflamación, dolor y acumulación de compuestos secundarios tóxicos, de enfermedades como el Alzheimer, el Parkinson y la Demencia. Por otra parte, la biodisponibilidad, los efectos adversos y las creencias personales corresponden a factores que dificultan la implementación del CBD en medicamentos. Finalmente, a pesar de que el CBD presenta amplios beneficios, se deben mejorar las vías de administración, la mitigación de efectos secundarios indeseados, y cambiar la percepción social sobre el uso medicinal de Cannabis sativa para facilitar su implementación como tratamiento regular de enfermedades neurodegenerativas.
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores conservan los derechos de autor y ceden a la revista el derecho de la primera publicación y pueda editarlo, reproducirlo, distribuirlo, exhibirlo y comunicarlo en el país y en el extranjero mediante medios impresos y electrónicos. Asimismo, asumen el compromiso sobre cualquier litigio o reclamación relacionada con derechos de propiedad intelectual, exonerando de responsabilidad a la Editorial Tecnológica de Costa Rica. Además, se establece que los autores pueden realizar otros acuerdos contractuales independientes y adicionales para la distribución no exclusiva de la versión del artículo publicado en esta revista (p. ej., incluirlo en un repositorio institucional o publicarlo en un libro) siempre que indiquen claramente que el trabajo se publicó por primera vez en esta revista.
Cómo citar
Referencias
[1] S. A. Syed et al., “International perspectives on physician knowledge, attitudes, and practices related to medical cannabis,” Frontiers in Public Health, vol. 13, p. 1463871, 2025, https://doi.org/10.3389/fpubh.2025.1463871.
[2] M. Savio, H. Kearney, y E. J. Downer, “Neurologists’ perspectives of cannabis-based medicines: results from an all-Ireland survey,” Irish Journal of Medical Science, vol. 194, no. 2, pp. 687-697, 2025, https://doi.org/10.1007/s11845-025-03880-0
[3] P. Sharma et al., “Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study,” PEC Innovation, vol. 1, p. 100044, Dic. 2022, https://doi.org/10.1016/j.pecinn.2022.100044
[4] S. Dahlke et al., “The Effects of Stigma: Older Persons and Medicinal Cannabis,” Qualitative Health Research, vol. 34, no. 8–9, pp. 717-731, Jul. 2024, https://doi.org/10.1177/10497323241227419
[5] S. Dahlke et al., “Understanding Older Adults’ Experiences with Cannabis for Medicinal Purposes: A Mixed Methods Study,” Canadian Journal on Aging / La Revue canadienne du vieillissement, vol. 44, no. 1, pp. 10–19, Mar. 2025, https://doi.org/10.1017/S0714980824000357
[6] F. T. Avoseh, F. M. Mtunzi, O. N. Avoseh, y S. Takaidza, “Cannabis sativa; Ethnobotanicals, Classifications, Pharmacology, and Phytochemistry,” Natural Product Communications, vol. 20, no. 6, Jun. 2025, https://doi.org/10.1177/1934578X251334244
[7] Y. Yang, R. Vyawahare, M. Lewis-Bakker, H. A. Clarke, A. H. C. Wong, y L. P. Kotra, “Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors,” Molecules, vol. 25, no. 15, p. 3466, Jul. 2020, https://doi.org/10.3390/molecules25153466
[8] K. M. Nelson et al., “The Essential Medicinal Chemistry of Cannabidiol (CBD),” Journal of Medicinal Chemistry, vol. 63, no. 21, pp. 12137–12155, Nov. 2020, https://doi.org/10.1021/acs.jmedchem.0c00724
[9] A. K. Schlag, C. Hindocha, R. Zafar, D. J. Nutt, y H. V. Curran, “Cannabis based medicines and cannabis dependence: A critical review of issues and evidence,” Journal of psychopharmacology (Oxford, England), vol. 35, no. 7, pp. 773–785, Jul. 2021, https://doi.org/10.1177/0269881120986393
[10] T. Cassano et al., “From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases,” Frontiers in Pharmacology, vol. 11, p. 515092, Mar. 2020, https://doi.org/10.3389/fphar.2020.00124
[11] N. Martinez Naya et al., “An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects,” Molecules, vol. 29, no. 2, p. 473, Ene. 2024, https://doi.org/10.3390/molecules29020473
[12] G. Madeo, A. Kapoor, R. Giorgetti, F. P. Busardò, y J. Carlier, “Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review,” Current neuropharmacology, vol. 21, no. 11, pp. 2323–2342, Mar. 2023, https://doi.org/10.2174/1570159X21666230322143401
[13] D. M. Wilson, M. R. Cookson, L. van den Bosch, H. Zetterberg, D. M. Holtzman, y I. Dewachter, “Hallmarks of neurodegenerative diseases,” Cell, vol. 186, no. 4, pp. 693–714, Feb. 2023, https://doi.org/10.1016/j.cell.2022.12.032
[14] R. Armstrong, “What causes neurodegenerative disease?,” Folia neuropathologica, vol. 58, no. 2, pp. 93–112, Jun. 2020, https://doi.org/10.5114/fn.2020.96707
[15] Z. Breijyeh, R. Karaman, D. Muñoz-Torrero, y R. Dembinski, “Comprehensive Review on Alzheimer’s Disease: Causes and Treatment,” Molecules, vol. 25, no. 24, p. 5789, Dic. 2020, https://doi.org/10.3390/molecules25245789
[16] R. N. L. Lamptey, B. Chaulagain, R. Trivedi, A. Gothwal, B. Layek, y J. Singh, “A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics,” International Journal of Molecular Sciences, vol. 23, no. 3, p. 1851, Feb. 2022, https://doi.org/10.3390/ijms23031851
[17] A. Duranti et al., “The Endocannabinoid System as a Target for Neuroprotection/Neuroregeneration in Perinatal Hypoxic–Ischemic Brain Injury,” Biomedicines, vol. 11, no. 1, p. 28, Ene. 2022, https://doi.org/10.3390/biomedicines11010028
[18] S. Schilling, R. Melzer, y P. F. McCabe, “Cannabis sativa,” Current Biology, vol. 30, no. 1, pp. R8–R9, Ene. 2020, https://doi.org/10.1016/j.cub.2019.10.039
[19] N. Martinez Naya, J. Kelly, G. Corna, M. Golino, A. Abbate, y S. Toldo, “Molecular and Cellular Mechanisms of Action of Cannabidiol,” Molecules, vol. 28, no. 16, p. 5980, Ago. 2023, https://doi.org/10.3390/molecules28165980
[20] E. D. Mock, B. Gagestein, y M. van der Stelt, “Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities,” Progress in Lipid Research, vol. 89, p. 101194, Ene. 2023, https://doi.org/10.1016/j.plipres.2022.101194
[21] A. Houldsworth, “Role of oxidative stress in neurodegenerative disorders: a review of reactive oxygen species and prevention by antioxidants,” Brain communications, vol. 6, no. 1, 2024, https://doi.org/10.1093/braincomms/fcad356
[22] P. Wen et al., “Oxidative stress and mitochondrial impairment: Key drivers in neurodegenerative disorders,” Ageing Research Reviews, vol. 104, p. 102667, Feb. 2025, https://doi.org/10.1016/J.ARR.2025.102667.
[23] S. Bhunia, N. Kolishetti, A. Y. Arias, A. Vashist, y M. Nair, “Cannabidiol for neurodegenerative disorders: A comprehensive review,” Frontiers in Pharmacology, vol. 13, p. 989717, Oct. 2022, https://doi.org/10.3389/FPHAR.2022.989717
[24] M. Ożarowski, T. M. Karpiński, A. Zielińska, E. B. Souto, y K. Wielgus, “Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action,” International Journal of Molecular Sciences 2021, vol. 22, no. 9, p. 4294, Abr. 2021, https://doi.org/10.3390/IJMS22094294.
[25] S. Khosropoor, M. S. Alavi, L. Etemad, y A. Roohbakhsh, “Cannabidiol goes nuclear: The role of PPARγ,” Phytomedicine, vol. 114, p. 154771, Jun. 2023, https://doi.org/10.1016/J.PHYMED.2023.154771.
[26] A. Vasincu et al., “Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty,” Biology, vol. 11, no. 3, p. 440, Mar. 2022, https://doi.org/10.3390/BIOLOGY11030440.
[27] A. Pugazhendhi et al., “Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review,” Process Biochemistry, vol. 111, pp. 9–31, Dic. 2021, https://doi.org/10.1016/J.PROCBIO.2021.08.025.
[28] C. Cattaneo y W. H. Jost, “Pain in Parkinson’s Disease: Pathophysiology, Classification and Treatment,” Journal of integrative neuroscience, vol. 22, no. 5, 2023, https://doi.org/10.31083/J.JIN2205132.
[29] K. Singh et al., “Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review,” Behavioural Neurology, vol. 2023, no. 1, p. 8825358, Ene. 2023, https://doi.org/10.1155/2023/8825358.
[30] S. Latif et al., “Dopamine in Parkinson’s disease,” Clinica Chimica Acta, vol. 522, pp. 114–126, Nov. 2021, https://doi.org/10.1016/J.CCA.2021.08.009.
[31] K. R. Gandhi y A. Saadabadi, “Levodopa (L-Dopa),” Encyclopedia of Psychopharmacology, pp. 898–899, Abr. 2023, https://doi.org/10.1007/978-3-642-36172-2_200303.
[32] L. di Biase, P. M. Pecoraro, S. P. Carbone, M. L. Caminiti, y V. di Lazzaro, “Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions,” Journal of Clinical Medicine, vol. 12, no. 13, p. 4427, Jun. 2023, https://doi.org/10.3390/JCM12134427.
[33] S. Silvestro, G. Schepici, P. Bramanti, y E. Mazzon, “Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease,” Molecules, vol. 25, no. 21, p. 5186, Nov. 2020, https://doi.org/10.3390/MOLECULES25215186.
[34] P. D. Emmady, C. Schoo, and P. Tadi, Major Neurocognitive Disorder (Dementia). Treasure Island: StatPearls Publishing, 2022. Accedido: Sept. 27, 2025. [En línea]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK557444/
[35] S. Pautex et al., “Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients,” Frontiers in Aging Neuroscience, vol. 14, p. 957665, Sept. 2022, https://doi.org/10.3389/fnagi.2022.957665
[36] F. Bianchi et al., “Medical cannabinoids for painful symptoms in patients with severe dementia: a randomized, double-blind cross-over placebo-controlled trial protocol,” Frontiers in Pain Research, vol. 4, p. 1108832, 2023, https://doi.org/10.3389/FPAIN.2023.1108832.
[37] M. Schouten, S. Dalle, D. Mantini, y K. Koppo, “Cannabidiol and brain function: current knowledge and future perspectives,” Frontiers in pharmacology, vol. 14, 2024, https://doi.org/10.3389/FPHAR.2023.1328885.
[38] E. Chesney et al., “Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials,” Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, vol. 45, no. 11, pp. 1799–1806, Oct. 2020, https://doi.org/10.1038/S41386-020-0667-2.
[39] J. D. R. Souza et al., “Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022),” Pharmaceutics, vol. 14, no. 12, p. 2598, Dic. 2022, https://doi.org/10.3390/pharmaceutics14122598